Rhumbline Advisers Aveo Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Aug 05, 2021	SELL	$6.21 - $7.45 $124,224 - $149,029	-20,004 Closed	0 $0
Q1 2021 May 06, 2021	BUY	$5.97 - $15.28 $435 - $1,115	73 Added 0.37%	20,004 $146,000
Q4 2020 Feb 10, 2021	BUY	$5.08 - $6.68 $32,451 - $42,671	6,388 Added 47.17%	19,931 $115,000
Q3 2020 Nov 12, 2020	BUY	$4.16 - $6.26 $894 - $1,345	215 Added 1.61%	13,543 $80,000
Q2 2020 Aug 13, 2020	BUY	$3.47 - $9.99 $46,248 - $133,146	13,328 New	13,328 $69,000

Ticker AVEO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 34,676,000
Description
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the ...

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

Stay updated on Rhumbline Advisers with notifications on news.